Jane Street Group LLC Boosts Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Jane Street Group LLC boosted its position in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 32.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 95,223 shares of the company's stock after acquiring an additional 23,286 shares during the quarter. Jane Street Group LLC owned about 0.16% of Inari Medical worth $3,927,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Vestal Point Capital LP increased its stake in shares of Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after acquiring an additional 1,200,000 shares during the period. Point72 Asset Management L.P. boosted its holdings in Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock valued at $71,324,000 after purchasing an additional 786,691 shares during the last quarter. Armistice Capital LLC grew its position in Inari Medical by 353.1% during the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock worth $48,595,000 after purchasing an additional 786,501 shares during the period. Jennison Associates LLC raised its stake in shares of Inari Medical by 63.2% during the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock valued at $65,021,000 after buying an additional 610,468 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Inari Medical by 101.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock valued at $32,790,000 after buying an additional 400,198 shares during the period. Hedge funds and other institutional investors own 90.98% of the company's stock.

Insider Activity at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company's stock, valued at $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the sale, the director now owns 601,233 shares of the company's stock, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 203,000 shares of company stock valued at $10,362,000. 10.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the company. Leerink Partners initiated coverage on Inari Medical in a report on Tuesday, September 3rd. They set a "market perform" rating and a $47.00 target price on the stock. Stifel Nicolaus began coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a "hold" rating and a $50.00 price objective on the stock. Canaccord Genuity Group boosted their target price on shares of Inari Medical from $71.00 to $74.00 and gave the company a "buy" rating in a research note on Tuesday, October 29th. Robert W. Baird increased their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday, October 29th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a report on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $61.80.

Inari Medical Stock Down 1.1 %

Shares of NASDAQ NARI traded down $0.62 during trading on Thursday, hitting $54.41. The company had a trading volume of 1,179,323 shares, compared to its average volume of 993,729. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -40.30 and a beta of 0.97. The stock has a fifty day simple moving average of $49.57 and a two-hundred day simple moving average of $48.08. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $66.61.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.